Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Heparin Dose Reduction During Hemodialysis With the Gambro Revaclear and Revaclear MAX Hemodialyzers: Pilot Study I and II

NCT01181544 is registered in ClinicalTrials.gov with Vantive Health LLC as lead sponsor.

NCT NCT01181544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01181544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Heparin Dose Reduction During Hemodialysis With the Gambro Revaclear and Revaclear MAX Hemodialyzers: Pilot Study I and II
Lead sponsor
Vantive Health LLC
Phase
Not applicable
Overall status
Completed
Start date
March 31, 2011
Completion date
August 31, 2011
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal failure chronic requiring hemodialysis